

MAR 16 2026

SENATE CONCURRENT RESOLUTION

REQUESTING THE AUDITOR TO ASSESS THE SOCIAL AND FINANCIAL
EFFECTS OF MANDATORY HEALTH INSURANCE COVERAGE FOR
BIOMARKER TESTING.

1 WHEREAS, biomarker testing is an invaluable tool in the
2 diagnosis, treatment, appropriate managements, and ongoing
3 monitoring of diseases or conditions; and
4

5 WHEREAS, biomarker testing is the analysis of a patient's
6 tissue, blood, or other biospecimen for the presence of a
7 biomarker, a type of precision medicine that looks for genes,
8 proteins, and other substances that can provide information
9 about a patient's chronic condition; and
10

11 WHEREAS, biomarker testing allows for a more precise and
12 personalized approach to medical care by identifying specific
13 genetic, molecular, or biochemical markers associated with an
14 individual's disease; and
15

16 WHEREAS, biomarker testing enables health care providers to
17 tailor treatments based on the unique characteristics of
18 a patient's condition, leading to more effective and targeted
19 interventions; and
20

21 WHEREAS, despite the fact that biomarker testing is
22 essential to high-quality, personalized care to treat serious
23 illness and enhance patients' quality of life, patients cannot
24 easily access it; and
25

26 WHEREAS, House Bill No. 1971, introduced in the Regular
27 Session of 2026, requires insurers, mutual benefit societies,
28 health maintenance organizations, and health plans under the
29 State's Medicaid managed care program to provide coverage for
30 medically necessary biomarker testing for the purposes of



1 diagnosis, treatment, appropriate management, or ongoing
2 monitoring of a person's disease or condition to guide treatment
3 decisions when supported by medical and scientific evidence; and
4

5 WHEREAS, pursuant to section 23-51, Hawaii Revised
6 Statutes, "before any legislative measure that mandates health
7 insurance coverage for specific health services, specific
8 diseases, or certain providers of health care services as part
9 of individual or group health insurance policies, can be
10 considered, concurrent resolutions shall be passed that
11 designate a specific legislative bill for the Auditor to review
12 and prepare a report for submission to the Legislature that
13 assesses both the social and financial effects of the proposed
14 mandated coverage" under that legislative bill; and
15

16 WHEREAS, section 23-52, Hawaii Revised Statutes, further
17 specifies the minimum information required for assessing the
18 social and financial impact of the proposed health coverage
19 mandate in the State Auditor's report; now, therefore,
20

21 BE IT RESOLVED by the Senate of the Thirty-third
22 Legislature of the State of Hawaii, Regular Session of 2026, the
23 House of Representatives concurring, that the Auditor is
24 requested to assess, in accordance with sections 23-51 and
25 23-52, Hawaii Revised Statutes, the social and financial effects
26 of mandating health insurance coverage for medically necessary
27 biomarker testing for the purposes of diagnosis, treatment,
28 appropriate management, or ongoing monitoring of a person's
29 disease or condition, or to guide treatment decisions when
30 supported by medical and scientific evidence, as provided in
31 House Bill No. 1971, Regular Session of 2026; and
32

33 BE IT FURTHER RESOLVED that the Auditor is requested to
34 submit a report of its findings and recommendations, including
35 any proposed legislation, to the Legislature no later than
36 twenty days prior to the convening of the Regular Session of
37 2027; and
38

39 BE IT FURTHER RESOLVED that certified copies of this
40 Concurrent Resolution be transmitted to the Auditor, Director of
41 Commerce and Consumer Affairs, and Insurance Commissioner.
42



S.C.R. NO. 76

1
2

OFFERED BY: Rachin Janda

